Stock News Applied Molecular Transport oral ulcerative colitis candidate fails in mid-stage trial admin Admin posted on 2 years ago — updated on 2 years ago 573 views AMT-101, an oral candidate for ulcerative colitis from Applied Molecular Transport (AMTI), has failed in a phase 2 trial. Applied Molecular Transport oral ulcerative colitis candidate fails in mid-stage trialDec. 22, 2022 6:19 PM ETApplied Molecular Transport Inc. (AMTI)By: Jonathan Block, SA News EditorFangXiaNuo/E+ via Getty Images admin Follow Comments Comment 0 comment Best Oldest Newest Write the first comment for this!
Comments
0 comment